Cardiovascular disease management during the coronavirus disease 2019 pandemic

Lee, Wen-Hsien; Chen, Ying-Chih; Chen, Szu-Chia; Chen, Chang-Jen; Hsu, Po-Chao; Tsai, Wei-Chung; Chu, Chun-Yuan; Lee, Chee-Siong; Lin, Tsung-Hsien; Voon, Wen-Chol; Kuo, Chao-Hung; Su, Ho-Ming

doi:10.7150/ijms.46484



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2020; 17(10):1340-1344. doi:10.7150/ijms.46484 This issue Cite

Review

Cardiovascular disease management during the coronavirus disease 2019 pandemic

Wen-Hsien Lee^1,2, Ying-Chih Chen¹, Szu-Chia Chen^1,2, Chang-Jen Chen¹, Po-Chao Hsu^2,3, Wei-Chung Tsai^2,3, Chun-Yuan Chu^2,3, Chee-Siong Lee^2,3, Tsung-Hsien Lin^2,3, Wen-Chol Voon^2,3, Chao-Hung Kuo^1,2, Ho-Ming Su^1,2,4✉

1. Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.
2. Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
3. Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
4. Regenerative Medicine and Cell Therapy Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan.

Citation:

Lee WH, Chen YC, Chen SC, Chen CJ, Hsu PC, Tsai WC, Chu CY, Lee CS, Lin TH, Voon WC, Kuo CH, Su HM. Cardiovascular disease management during the coronavirus disease 2019 pandemic. Int J Med Sci 2020; 17(10):1340-1344. doi:10.7150/ijms.46484. https://www.medsci.org/v17p1340.htm

Other styles

Abstract

Based on clinical presentation, pathophysiology, high infectivity, high cardiovascular involvement, and therapeutic agents with cardiovascular toxicity of coronavirus disease 2019 (COVID-19), regular cardiovascular treatment is being changing greatly. Despite angiotensin-converting enzyme 2 serving as the portal for infection, the continuation of clinically indicated renin-angiotensin-aldosterone blockers is recommended according to the present evidence. Fibrinolytic therapy can be considered a reasonable option for the relatively stable ST segment elevation myocardial infarction (STEMI) patient with suspected or known COVID-19. However, primary percutaneous coronary intervention is still the standard of care in patients with definite STEMI if personal protective equipment is available and cardiac catheterization laboratory has a good infection control. In patients with elevated cardiac enzymes, it is very important to differentiate patients with Type 2 myocardial infarction or myocarditis from those with true acute coronary syndromes because invasive percutaneous intervention management in the former may be unnecessary, especially if they are hemodynamically stable. Finally, patients with baseline QT prolongation or those taking QT prolonging drugs must be cautious when treating with lopinavir/ritonavir and hydroxychloroquine for COVID-19.

Keywords: coronavirus, cardiovascular, pandemic

Citation styles

APA

Lee, W.H., Chen, Y.C., Chen, S.C., Chen, C.J., Hsu, P.C., Tsai, W.C., Chu, C.Y., Lee, C.S., Lin, T.H., Voon, W.C., Kuo, C.H., Su, H.M. (2020). Cardiovascular disease management during the coronavirus disease 2019 pandemic. International Journal of Medical Sciences, 17(10), 1340-1344. https://doi.org/10.7150/ijms.46484.

ACS

Lee, W.H.; Chen, Y.C.; Chen, S.C.; Chen, C.J.; Hsu, P.C.; Tsai, W.C.; Chu, C.Y.; Lee, C.S.; Lin, T.H.; Voon, W.C.; Kuo, C.H.; Su, H.M. Cardiovascular disease management during the coronavirus disease 2019 pandemic. Int. J. Med. Sci. 2020, 17 (10), 1340-1344. DOI: 10.7150/ijms.46484.

NLM

CSE

Lee WH, Chen YC, Chen SC, Chen CJ, Hsu PC, Tsai WC, Chu CY, Lee CS, Lin TH, Voon WC, Kuo CH, Su HM. 2020. Cardiovascular disease management during the coronavirus disease 2019 pandemic. Int J Med Sci. 17(10):1340-1344.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.